{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-401110","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2026-09-24T20:38:40+00:00","discovered_at":"2026-09-24T20:39:12.546843+00:00","generated_at":"2026-09-24T20:39:19.542219+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Benitec Biopharma dismisses Baker Tilly, appoints Ernst & Young as auditor","bullets":["Dismissed Baker Tilly on Sept 18, 2026; appointed EY for fiscal year ending June 30, 2027.","Baker Tilly's FY2025/FY2026 audit reports were unqualified, with no disagreements.","Prior material weakness in share-based compensation controls was remediated as of June 30, 2026.","No consultations with EY on accounting matters; engagement subject to EY client acceptance.","Company cites good corporate governance as reason for auditor transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-401110","json":"https://secwatch.observer/filing/0001193125-26-401110.json","markdown":"https://secwatch.observer/filing/0001193125-26-401110.md","text":"https://secwatch.observer/filing/0001193125-26-401110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312526401110/0001193125-26-401110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312526401110/bntc-20260918.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-24T20:39:19.542219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}